SAN DIEGO , Aug. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
SAN DIEGO , July 25, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces that it will release financial results for the three and six months ended June 30, 2016
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
SAN DIEGO , Nov. 4, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020 after the
SAN DIEGO , Oct. 31, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release
SAN DIEGO , Nov. 2, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
SAN DIEGO , June 5, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate
SAN DIEGO --(BUSINESS WIRE)--Mar. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020 after the market closes on Monday, March 29, 2021
SAN DIEGO --(BUSINESS WIRE)--Mar. 18, 2022-- Biocept, Inc. (Nasdaq: BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022 .
